SGC Press Releases

FFAR Awards $1 Million Grant to Create Open Source Technology for Gene Discovery in Plants

Monday 4th December 2017

The Foundation for Food and Agriculture Research (FFAR), a nonprofit established in the 2014 Farm Bill with bipartisan congressional support, awarded a $1 million Seeding Solutions grant to University of California, Davis (UC Davis) to study the genetics of rice plants. Together with researchers at the University of North Carolina and collaborators, the team will develop and implement a chemistry-driven gene discovery approach to identify genes that modulate root traits.

Takeda and SGC Announce a Collaboration Agreement Using Patient Tissue-Based Assays for Clinical Target Validation in Irritable Bowel Disease

Thursday 28th September 2017

Osaka, Japan, San Diego, Calif., USA, and Stockholm, Sweden, September 28, 2017— Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), Karolinska Institutet (“KI”) and The Structural Genomics Consortium (“SGC”) today announced a combined pre-competitive and proprietary collaboration to discover and validate new potential intervention points for the treatment of Inflammatory Bowel Disease (IBD).

DiscoverX and the SGC Announce Major Milestone in Development of Kinase Chemogenomic Set

Friday 4th August 2017

FREMONT, Calif., Aug. 3, 2017 /PRNewswire/ -- DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, in collaboration with the Structural Genomics Consortium (SGC) at the University of North Carolina at Chapel Hill today announced the completion of an important milestone and extension of their partnership to develop selective and potent chemical probes for the unexplored human kinome.

New support for Structural Genomics Consortium and open science

Monday 12th June 2017

3D map of PC2 to jump-start drug discovery efforts in polycystic kidney disease

Monday 19th December 2016

http://www.nature.com/nsmb/journal/vaop/ncurrent/full/nsmb.3343.html

Oxford, UK, December 19, 2016, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes autosomal dominant polycystic kidney disease (ADPKD) when mutated, in an article published today in Nature Structural and Molecular Biology.

Oxford AHSN recognizes the SGC with its annual Public-Private Collaboration Award

Friday 7th October 2016

Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.

The SGC releases its first crop of TEPs to accelerate drug discovery

Monday 12th September 2016

Target-enabling packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria

The Brain Tumour Charity and the SGC announce the first open-access collaboration in European brain tumour research

Wednesday 13th April 2016

We are delighted to announce a groundbreaking partnership between The Brain Tumour Charity and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and initiating clinical trials within unusually short timeframes.

DiscoverX and the SGC Partner to Make an Annotated Collection of >600 Kinase Inhibitors Freely Available

Monday 29th February 2016

DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced its partnership with the Structural Genomics Consortium (SGC), a public-private organization established in 2003, to develop selective and potent chemical probes for the unexplored human kinome and to promote open sharing of these probes with the scientific community.

Stand Up To Cancer Canada Announces New Cancer Stem Cell Dream Team To Attack Brain Cancer in Children and Adults

Thursday 4th February 2016

Pan-Canadian Team of Researchers Will Receive CA$11.7 Million in Funding from Stand Up To Cancer Canada, Genome Canada, Canadian Institutes of Health Research, Cancer Stem Cell Consortium, and Ontario Institute for Cancer Research